SCHEDULE: Driehaus Capital Management Reduces Stake in Crinetics Pharmaceuticals

Driehaus Capital Management LLC has filed an amendment to its Schedule 13G, reporting a decrease in its beneficial ownership of Crinetics Pharmaceuticals, Inc. common stock to 6.11% as of March 31, 2026.

Summary

• Driehaus Capital Management LLC (DCM) has filed an amendment to its Schedule 13G, indicating a change in its ownership of Crinetics Pharmaceuticals, Inc. (CRNX) common stock.
• As of March 31, 2026, DCM beneficially owns 6,395,922 shares, representing 6.11% of the class of securities.
• This represents a decrease from its previous ownership of 7.54% as of December 31, 2023.
• DCM manages these shares on a fully discretionary basis for numerous clients.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative sentiment due to the reduction in ownership by a significant institutional investor, though it is a routine filing and not indicative of fundamental company distress.

Negatives

• Driehaus Capital Management LLC has reduced its ownership stake in Crinetics Pharmaceuticals, Inc. from 7.54% to 6.11%.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it solely reports on current beneficial ownership changes.

Management Comments

• "This amendment is filed to reflect the change in our percentage of ownership of Crinetics Pharmaceuticals, Inc. (CRNX). DCM owned 6.11% of CRNX as of March 31, 2026, down from 7.54% as of December 31, 2023."
• "The shares reported by Driehaus Capital Management LLC (DCM) are held by numerous clients on a fully discretionary basis in accounts managed by DCM."
• "To the best of DCM's knowledge, none of the referenced clients have the right to receive dividends or direct proceeds from the sale of interests relating to more than 5% of the class."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

StockSavvy.ai notes that changes in significant institutional ownership, such as this reduction by Driehaus Capital Management, can be a signal to the market regarding an investment firm's conviction or strategic reallocation, potentially influencing investor sentiment towards Crinetics Pharmaceuticals.

Stakeholder Impact

• Shareholders may interpret the reduction in ownership by Driehaus Capital Management as a signal of reduced confidence or a strategic shift, potentially impacting share price. However, the filing also states the shares are held for numerous clients on a discretionary basis, suggesting it may not reflect a fundamental view on Crinetics's long-term prospects.

Key Dates

Recommendation

The filing is a routine disclosure of ownership changes by an institutional investor and does not contain operational or financial performance data for Crinetics Pharmaceuticals. Therefore, a 'hold' recommendation is appropriate, pending further information on the company's performance and the reasons behind the investor's stake reduction.

Keywords

Crinetics Pharmaceuticals, Driehaus Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Management